PETReA

 Non-Hodgkin lymphoma / Posted 12 months ago

PETReA: A study to find out whether a PET-CT scan can help to tell who needs to have rituximab after the initial treatment for lymphoma.

Follicular Lymphoma is a type of non Hodgkin lymphoma (NHL). Doctors usually put NHL into 2 groups, depending on how likely they are to grow and spread. The 2 groups are low grade and high grade NHL. Follicular lymphoma is a type of low grade NHL.

For follicular lymphoma, you usually have treatment with a combination of cancer drugs. You might have one of the following:

This is called the induction treatment. After the induction treatment, you might have rituximab (R) alone. This is the maintenance phase. But having more treatment with rituximab doesn’t help everyone with follicular lymphoma.

Doctors would like to know who needs to have rituximab after their initial treatment (induction). In this study, they are looking at whether PET-CT scans can help them to decide who needs to have maintenance rituximab.

 

  • Inclusion Criteria :
    • you have follicular lymphoma that is grade 1, 2 or 3a
    • your lymphoma is in at least 2 groups of lymph nodes (stage 2, 3 or 4)
    • you have a high number of lymphoma cells (a high tumour burden) – your doctor can tell you more about this
    • you are going to have treatment that reaches your whole body (systemic) for the first time
    • you have satisfactory blood tests results
    • your kidneys are working well
    • are well enough to be up and about for at least half of the day (performance status 0, 1 or 2)
    • you are willing to use reliable contraception during treatment if there is any possibility that you or your partner could become pregnant
    • are at least 18 years old
  • Exclusion Criteria :
    • have lymphoma in the brain or the spinal cord
    • have had another cancer in the past 5 years apart from successfully treated carcinoma in situ of the cervix, breast and prostate, and non melanoma skin cancer
    • have HIV
    • have hepatitis B or hepatitis C
    • have any other serious medical condition that the trial team think could affect you taking part
    • have had a live vaccine in the past month
    • are pregnant or breastfeeding
  • Study start date : 10/05/2018
  • Study end date : 30/09/2022
  • Wales-Based Study Contact : please speak to your clinician
  • Principal Investigator : Professor Andrew Pettitt
Contact details

Blackpool, Boston, Canterbury, Colchester, Derby, Epsom, Gillingham, Glasgow, Grantham, Leicester, Lincoln, Liverpool, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford, Plymouth, Poole, Portsmouth, Sheffield, Southampton, Southend on Sea, Thornton, Torquay, Truro, Wales, Wirral.Wales Wide www.cancerresearchuk.org

No post found